MUMBAI, India, January 7 /PRNewswire/ --
- Company Receives its First Controlled Substance Product Approval
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that together with its subsidiaries, it has received final approval from USFDA for several Abbreviated New Drug Applications (ANDA). Approval was received for generic hydocodone bitartate with acetaminophen (APAP) tablets. Approval was also received for generic Aredia(R), pamidronate disodium for injection USP, generic Lopid (R), gemfibrozil tablets, USP, and generic Phenargan(R), promethazine hydrochloride tablets.
First Controlled Substance approval